In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk
- PMID: 37665995
- DOI: 10.7326/J23-0069
In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk
Abstract
Loftus EV Jr, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023;388:1966-1980. 37224198.
Conflict of interest statement
Comment on
-
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.N Engl J Med. 2023 May 25;388(21):1966-1980. doi: 10.1056/NEJMoa2212728. N Engl J Med. 2023. PMID: 37224198 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical